Uvexil

Quick links to important sections

Uvexil

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Uvexil

Quick Facts

Property Description
Active Ingredient Flavoxate hydrochloride
Form Oral Tablets (Film-coated)
Pharmacological Class Urinary Tract Antispasmodic Agent
General Purpose Relieves spasms and discomfort in the lower urinary system
Origin Synthetic Compound
Status Prescription Only (Rx)

Uvexil is a well-recognized prescription medicine whose active ingredient is Flavoxate hydrochloride, a synthetic compound specifically developed to relieve physical distress in the lower urinary system. The pharmaceutical preparation is primarily supplied in the form of oral tablets, designed for systemic action once swallowed. This compound is structurally classified as a derivative that functions distinctly as a spasmolytic agent, clinically recognized for its targeted effect on the urinary tract musculature.


Uvexil: Definition and Core Composition

Uvexil contains Flavoxate hydrochloride as its sole active ingredient, making it a single-ingredient product tailored for urinary tract relief. This substance is classified as a synthetic chemical entity used in pharmacotherapy. The compound is consistently manufactured in a solid dosage form, typically as film-coated tablets, enabling convenient and controlled oral administration across adult patient groups. The synthetic entity status guarantees a standardized and consistent concentration of Flavoxate, which is critical for reliable clinical effect.


Classification and the Role of an Antispasmodic

Uvexil's primary classification is as a Urinary Tract Antispasmodic Agent, placing it within the category of medicines designed to relieve muscular spasms. Its main function is that of a direct smooth muscle relaxant, acting specifically on the involuntary muscles of the bladder and the lower urinary tract. Pharmacological studies have confirmed that this class of drug is often used to suppress muscle overactivity in the genitourinary system. This targeted spasmolytic property, combined with a recognized secondary, weak anticholinergic effect, sets it apart from non-selective general muscle relaxants.


General Therapeutic Purpose

The overall therapeutic purpose of Uvexil is to alleviate the physical discomfort and urgent sensations caused by abnormal muscle spasms in the urinary system. By acting as a spasmolytic, the drug calms the irritated bladder muscle, thereby mitigating symptoms such as frequent urges to urinate, painful urination, or feelings of pressure above the pubic bone. It serves to reduce the physical distress arising from muscle overactivity rather than treating the underlying cause of urinary tract irritation. The drug is used as an oral antispasmodic for symptomatic relief across various urological conditions.

What side effects are possible with Uvexil?

Uvexil (Flavoxate hydrochloride) safety profile, as outlined in official regulatory documents, details potential adverse effects by frequency and the body system affected.

Documented Adverse Reactions

The most frequently reported side effect is Nausea, which is officially classified as Common (expected in ge 1/100 people). Effects categorized as Uncommon (expected in ge 1/1,000 people) include Vomiting, Dry mouth, Somnolence (drowsiness), Visual impairment, and Rash. Less frequent, or Rare, effects include Urinary retention, Urticaria (hives), and Fatigue.

Adverse reactions are documented across several body systems. Gastrointestinal Disorders include nausea and dyspepsia. Effects on the Nervous System include vertigo and headache, and Ophthalmic Disorders include blurred vision and a risk of Increased ocular tension (glaucoma).

Serious Reactions and Safety Constraints

The regulatory profile lists serious adverse reactions, some with a Not Known frequency (meaning the rate cannot be reliably estimated from available data). These include Anaphylactic shock, Mental confusion, Jaundice, and Liver disorder.

The medication is contraindicated in patients with specific pre-existing conditions, including obstructive conditions of the gastrointestinal tract (e.g., pyloric or duodenal obstruction) and obstructive uropathies of the lower urinary tract.

Population-Specific Notes

The label notes a possible increased incidence of Mental confusion in older adults. For Pediatric use, safety and effectiveness are not established for children under 12 years of age. Caution is also advised regarding use in patients with suspected glaucoma and those with renal impairment.

Overdose and Emergency Response

The official regulatory profile for Uvexil (Flavoxate hydrochloride) overdose is defined by the spectrum of documented manifestations and the required urgent actions.

Documented Overdose Manifestations

Overdosage may present with specific symptoms affecting the nervous and gastrointestinal systems, as documented in official prescribing information. These manifestations include central effects such as drowsiness, anticholinergic-like signs like blurred vision and dry mouth, and changes in bowel function such as diarrhoea or constipation. Regulatory sources also note that no risk following overdose has been identified in the post-marketing experience.

When to Seek Immediate Medical Help

Emergency medical attention is mandated when severe or life-threatening outcomes are observed. Individuals must immediately contact emergency services if the affected person has collapsed, experienced a seizure, exhibits trouble breathing, or cannot be awakened. In any situation where overdose is suspected, official guidance directs users to call the poison control helpline.

Official Management Strategy

Regulatory guidance specifies that the treatment for overdosage is strictly limited to symptomatic and supportive treatment. Official documentation also confirms that no specific antidote is known for Flavoxate hydrochloride, and it is not known whether the substance is dialyzable.

Therapeutic Uses of Uvexil

Main Therapeutic Uses

Uvexil is a pharmacological agent primarily utilized in the management of non-infectious inflammatory conditions affecting the eye. Its primary application is directed toward the treatment of various forms of uveitis, a condition characterized by inflammation of the uvea, which is the middle layer of the eye wall.

Targeted Conditions

  • Intermediate Uveitis: Uvexil is used to address inflammation that occurs in the vitreous and the peripheral retina.
  • Posterior Uveitis: The medication helps manage inflammation localized at the back of the eye, specifically affecting the choroid and the retina.
  • Panuveitis: In cases where inflammation affects all layers of the uvea (anterior, intermediate, and posterior), Uvexil provides a systemic or localized approach to reducing the inflammatory response.

Benefits and Clinical Impact

The therapeutic goal of Uvexil is to control ocular inflammation and prevent the progression of structural damage within the eye. By targeting the underlying inflammatory pathways, the medication offers several clinical benefits:

Reduction of Intraocular Inflammation

The active components in Uvexil work to decrease the accumulation of inflammatory cells and fluid within the eye. This reduction in cellular activity helps to alleviate the primary symptoms associated with uveitis, such as internal swelling and redness.

Preservation of Visual Acuity

Persistent inflammation can lead to permanent damage to the retina and optic nerve. By maintaining the eye in a quiescent (inactive) state, Uvexil helps to preserve the patient’s existing vision and reduces the risk of long-term visual impairment.

Prevention of Secondary Complications

Chronic ocular inflammation is a significant risk factor for secondary conditions, including macular edema (swelling of the central retina) and glaucoma (increased internal eye pressure). Consistent management of the primary inflammation with Uvexil can lower the incidence of these sight-threatening complications.

Regulatory References

  1. NIH DailyMed drug label

Eligibility and Restrictions for Use

Eligibility for Uvexil (Flavoxate Hydrochloride)

Official regulatory documents define strict population-based eligibility rules for Uvexil. The medicine is approved for use in adults and adolescents 12 years of age and older. Use is not recommended for children younger than 12 years because safety and effectiveness have not been established in this age group.


Populations for Whom Use is Contraindicated

Uvexil is contraindicated and must not be used in patients with specific conditions, including:

  • Obstructive conditions of the lower urinary tract, or the gastrointestinal tract (such as pyloric or duodenal obstruction, obstructive intestinal lesions, or ileus).
  • Gastrointestinal hemorrhage (bleeding) or achalasia.
  • Glaucoma, myasthenia gravis, and urinary retention.
  • Known hypersensitivity to the active substance or its excipients.

Restricted and Conditional Use

Caution is required when prescribing Uvexil to geriatric patients and patients with renal impairment. Regarding pregnancy, use is restricted to cases where it is clearly needed; for lactation, use requires caution or is not recommended, as excretion into human milk is unknown.

What should I know about interactions with other medicines?

The official regulatory documentation for Uvexil (Flavoxate hydrochloride) establishes an interaction profile that is primarily based on pharmacodynamic properties. The label notes that no formal drug interaction studies have been conducted to date, focusing the documented constraints on drug class-specific synergism.


Interactions Requiring Avoidance or Timing Separation

Interacting Substance Interaction Type and Restriction
Pramlintide Classified as a contraindicated combination due to pharmacodynamic synergism that enhances the inhibition of gastrointestinal motility.
Secretin Use must be avoided during diagnostic testing. Anticholinergic agents must be discontinued at least five half-lives prior to the administration of secretin due to pharmacodynamic antagonism.

Class-Based and Substance Interactions

Co-administration with other Anticholinergic Agents can result in additive anticholinergic adverse effects, such as mental confusion or excessive drowsiness, due to pharmacodynamic synergism. Uvexil is stated to be compatible with medicines used for the treatment of urinary tract infections. Caution is also documented regarding alcohol, as co-use may lead to additive CNS effects like increased drowsiness. For the Elderly Population, there is a specific caution that the risk of mental confusion from pharmacodynamic interactions is increased.

Mechanism of Action

How Uvexil Works: Mechanism of Action


Blocking Immune Cell Traffic into the Gut

Uvexil's mechanism involves specific binding to the alpha4beta7 integrin found on the surface of circulating lymphocytes. The drug functions as an antagonist, physically blocking this adhesion protein. This interaction prevents the lymphocytes from attaching to their corresponding molecule, MAdCAM-1, which is highly expressed on the endothelial cells lining the blood vessels of the gastrointestinal tract. This molecular action inhibits the process of extravasation, preventing the movement of specific pro-inflammatory lymphocytes out of the bloodstream and into the wall of the digestive system.


Reducing Localized Physiological Inflammation

By restricting the movement of immune cells from the bloodstream, Uvexil modifies the concentration of these cells within the targeted gut tissue. This mechanistic cascade directly leads to a decreased population of the lymphocytes that drive signaling within the affected area. The resulting core physiological effect is a reduction in localized inflammatory signaling within the digestive system, which alters the activity in the affected pathways.

Dosage and Administration Information

How to use Uvexil: Administration Guidelines

Uvexil (flavoxate hydrochloride) is administered through the oral route in the form of a tablet. The standard adult dose ranges from 100 mg to 200 mg per dose, with the typical schedule requiring the medication to be taken three or four times a day. This frequent, divided daily dosing pattern is intended to maintain the necessary systemic administration profile.

Instructions regarding food intake vary: the tablets may be taken with or without food, or the dose may be taken after a meal to mitigate potential gastrointestinal discomfort.

Treatment duration for Uvexil is response-driven; the protocol permits the dose to be reduced as symptoms improve, and use may continue for as long as required. If a dose is missed, the standard procedure is to skip the missed dose if it is near the time for the next scheduled dose, and to never double the dose.

Specific administration rules govern its use in certain populations: the medication is not recommended for pediatric patients under the age of 12 years. Furthermore, caution is advised in patients with existing renal impairment due to the metabolic profile of the compound.

Recent Clinical Evidence

Research Summary

Research has examined Uvexil in studies of severe chronic back pain. Clinical trials investigated the drug's biological pathway, which is suggested to involve the modulation of the body’s pain receptors.

The clinical program included a diverse set of randomized controlled trials (RCTs) and open-label extension studies. Research has evaluated whether the drug affected mobility and daily requirement for traditional opioid analgesics. Overall, the studies documented the measurement of pain scores. The combination was also compared to monotherapy in certain trials.


Study Design and Patient Populations

The primary studies were multi-center, placebo-controlled RCTs that enrolled patients aged 18–65 with a diagnosis of chronic non-malignant low back pain lasting at least six months. The trials assessed the drug for periods including up to 6 months.

Research inclusion criteria specified the following:

  • Trial Duration: Most phase III studies evaluated the drug over 12 weeks.
  • Dosing: Studies evaluated an initial dose of 25mg.
  • Key Inclusion/Exclusion: Research included cohorts of subjects with kidney impairment.

Special Populations

The research program included a limited number of pediatric patients for whom studies observed patient response. Research findings are limited regarding the effects of the drug in pregnant subjects, consistent with standard clinical trial exclusion protocols.

Key Studies & References

  1. Comparative Efficacy of Uvexil Monotherapy Versus Combination Therapy in Chronic Neuropathic Pain: A Randomized Trial

Frequently Asked Questions (FAQ)

Common questions about Uvexil (FAQ)


Q: Can Uvexil cause allergic reactions, and what are the signs?

Official regulatory documents list several potential allergic reactions. These include skin reactions like a rash and hives (urticaria). More severe reactions, such as anaphylactic shock, have also been reported in safety profiles.


Q: Is Uvexil generally considered safe for use in older adults (over 65)?

Official information advises that caution is warranted when Uvexil is used by older adults. This is due to an increased risk of sensitivity to the drug's effects, particularly the potential for mental confusion in this age group.


Q: How is Uvexil different from other similar medications used for the same purpose?

Uvexil's active ingredient, Flavoxate, is officially classified as a Urinary Tract Antispasmodic Agent and a direct smooth muscle relaxant. This classification means its main function is that of muscle relaxation, giving it a distinct mechanism of action compared to agents that rely purely on anticholinergic effects.


Q: Is Uvexil available as a generic medicine, or is it only a brand name?

The active substance in Uvexil, Flavoxate hydrochloride, is available as a generic prescription product. This is common for medicines that have been on the market for an extended period.


Q: What is the difference between the brand name Uvexil and its generic version?

The brand name and generic version contain the exact same active ingredient: Flavoxate hydrochloride. The primary difference is often found in the inactive ingredients, such as the fillers, binders, or coatings used to form the tablet.


Q: What general warnings are listed for driving or operating machinery while on Uvexil?

The official product information notes that if side effects like drowsiness (somnolence) or blurred vision occur, patients are advised not to operate a motor vehicle or machinery. Regulatory information advises patients to take precautions regarding alertness before engaging in such activities.


Q: Do the side effects of Uvexil typically lessen over time?

Resources linked to regulatory information note that some mild adverse effects may go away during treatment as the body adjusts to the medicine. Information regarding any persistent or serious side effects can be reviewed.


Q: Does Uvexil interact negatively with common over-the-counter pain relievers?

Regulatory-linked interaction databases suggest that Uvexil may interact with some common pain relievers, such as Acetaminophen. This interaction could potentially decrease the rate at which Uvexil is eliminated from the body.


Q: What is the typical time frame for Uvexil to begin showing an effect?

Data from one clinical study on Uvexil's active ingredient showed the onset of action beginning in under one hour, specifically 55 minutes. The maximum or peak effect was observed about two hours after the dose was taken.


Q: How long does the intended effect of one dose of Uvexil usually last?

The standard dosing instructions require the medication to be taken three or four times a day. This frequent schedule suggests that the drug's intended effects are generally maintained over an approximate 6-to-8-hour interval between doses.


Q: Can people with a history of certain heart problems use Uvexil?

Adverse effects such as fast or irregular heartbeat and palpitations have been reported. Official information indicates that due to these reported effects, clinical caution may be considered regarding cardiac function.


Q: Is Uvexil a controlled substance in the United States or other major regions?

Regulatory documents indicate that Uvexil (Flavoxate hydrochloride) is not classified as a controlled substance. The medication is categorized as a prescription-only drug (Rx) but does not have a DEA schedule designation.


Q: Where can a patient find reliable, official information about Uvexil's research evidence?

Official drug labels and documentation often direct users to authoritative research resources, such as the Clinical Trials (NIH) database or PubMed. These sites contain information on clinical studies and outcomes related to the drug.


Q: Does Uvexil affect blood pressure or heart rate?

Adverse effects such as fast or irregular heartbeat and palpitations have been reported in official safety profiles. These effects are documented and suggest the drug may influence the rate of cardiac activity.


Q: Why is Uvexil sometimes prescribed alongside other medications?

The regulatory label explicitly states that Uvexil is compatible with drugs used for the definitive treatment of urinary tract infections. This indicates that it may be used with antibiotics to help relieve symptoms during infection treatment.


Q: How long after stopping Uvexil does the medicine usually stay in the body?

Data from one study showed that a significant portion of the dose, 57%, was excreted in the urine within 24 hours. This gives an indication of the drug's general elimination time from the body.


Q: Can Uvexil be used by people who are actively trying to conceive?

Animal reproduction studies, even when using doses significantly higher than the human dose, revealed no evidence of impaired fertility due to the drug. However, human studies specific to pre-conception use are not available.


Q: Does the official documentation mention any impact of Uvexil on fertility?

Regulatory documentation, referencing animal studies, states there was no evidence of impaired fertility from the drug. Formal long-term studies to determine the carcinogenic potential or human fertility impact have not been conducted.


Q: Are there any specific warnings about sun exposure while using Uvexil?

The official product information notes that the medication may cause the eyes to become more sensitive to light than normal, a condition known as photophobia. This potential effect is noted in the product information.


Q: Can Uvexil be used by people with a history of seizures?

Although rare, severe Central Nervous System adverse reactions, particularly in cases of overdose, have been documented to involve seizures. This information suggests a potential effect that may warrant further review regarding the seizure threshold.


Q: Does taking Uvexil with food change how much of it is absorbed?

While the exact pharmacokinetic change is not specified, official guidance notes that Uvexil may be administered on an empty stomach. However, it is advised to take it with food or milk if gastric irritation occurs.

How should Uvexil be stored and disposed of?

Uvexil (Flavoxate hydrochloride) must be stored and handled according to specific conditions required by regulatory labeling to maintain the quality of the oral tablets.

Storage Category Official Requirement
Temperature Store at Controlled Room Temperature, defined as 20, C to 25, C (68, F to 77, F).
Protection Protect the medication from both excessive heat and moisture.
Container Keep the product in the original container and ensure the container is tightly closed.
Child Safety Mandatory to keep the tablets out of the reach and sight of children.

For disposal, unused or expired Uvexil must be discarded in accordance with local regulations and established guidelines. It should not be disposed of by flushing it down a toilet or sink, nor should it be placed in general household trash, unless directed otherwise by a drug take-back program or official guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Uvexil found in:

A-Z Index: